Private Advisor Group LLC Has $3.35 Million Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

Private Advisor Group LLC boosted its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 18.5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 85,036 shares of the company’s stock after purchasing an additional 13,289 shares during the period. Private Advisor Group LLC owned 0.10% of CRISPR Therapeutics worth $3,347,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Highline Wealth Partners LLC acquired a new stake in shares of CRISPR Therapeutics in the fourth quarter valued at $39,000. Western Pacific Wealth Management LP grew its holdings in CRISPR Therapeutics by 100.0% during the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock worth $39,000 after acquiring an additional 500 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in CRISPR Therapeutics in the 3rd quarter valued at about $40,000. Darwin Wealth Management LLC bought a new position in shares of CRISPR Therapeutics in the third quarter worth about $43,000. Finally, Spire Wealth Management raised its stake in shares of CRISPR Therapeutics by 303.7% in the fourth quarter. Spire Wealth Management now owns 1,970 shares of the company’s stock worth $78,000 after acquiring an additional 1,482 shares during the last quarter. Institutional investors own 69.20% of the company’s stock.

Insider Buying and Selling at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 18,360 shares of the firm’s stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $55.20, for a total value of $1,013,472.00. Following the completion of the transaction, the chief executive officer now owns 171,613 shares in the company, valued at $9,473,037.60. This trade represents a 9.66 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 4.10% of the company’s stock.

Analysts Set New Price Targets

CRSP has been the subject of a number of research reports. Stifel Nicolaus lowered their price target on shares of CRISPR Therapeutics from $53.00 to $49.00 and set a “hold” rating for the company in a report on Thursday, February 13th. Citigroup lowered their target price on CRISPR Therapeutics from $89.00 to $82.00 and set a “buy” rating for the company in a research note on Tuesday, February 18th. TD Cowen raised CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 price target on the stock in a research note on Wednesday, February 12th. Bank of America lowered their price objective on CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Finally, The Goldman Sachs Group cut their target price on shares of CRISPR Therapeutics from $66.00 to $57.00 and set a “neutral” rating on the stock in a research report on Thursday, February 13th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $74.40.

CRISPR Therapeutics Trading Down 5.0 %

NASDAQ:CRSP opened at $47.91 on Monday. CRISPR Therapeutics AG has a 1 year low of $36.52 and a 1 year high of $91.10. The stock has a 50-day moving average price of $42.25 and a two-hundred day moving average price of $46.03. The stock has a market cap of $4.11 billion, a price-to-earnings ratio of -10.96 and a beta of 1.67.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. Sell-side analysts forecast that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.